作者
Shabir A Madhi, Vicky Baillie, Clare L Cutland, Merryn Voysey, Anthonet L Koen, Lee Fairlie, Sherman D Padayachee, Keertan Dheda, Shaun L Barnabas, Qasim E Bhorat, Carmen Briner, Gaurav Kwatra, Khatija Ahmed, Parvinder Aley, Sutika Bhikha, Jinal N Bhiman, As’ ad E Bhorat, Jeanine Du Plessis, Aliasgar Esmail, Marisa Groenewald, Elizea Horne, Shi-Hsia Hwa, Aylin Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Masebole Masenya, Mduduzi Masilela, Shakeel McKenzie, Kgaogelo Molapo, Andrew Moultrie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Lindie Rossouw, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Samuel Van Eck, Constantinos K Wibmer, Nicholas M Durham, Elizabeth J Kelly, Tonya L Villafana, Sarah Gilbert, Andrew J Pollard, Tulio De Oliveira, Penny L Moore, Alex Sigal, Alane Izu
发表日期
2021/5/20
期刊
New England Journal of Medicine
卷号
384
期号
20
页码范围
1885-1898
出版商
Massachusetts Medical Society
简介
Background
Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa.
Methods
We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×1010 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization …
学术搜索中的文章
SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen… - New England Journal of Medicine, 2021